Strong Revenue Growth in Core Business
Achieved 40% growth in recurring core businesses with revenues over $6 million, compared to $4.3 million the prior year. This was primarily from recurring sales.
Expanded Gross Margins
Gross margins expanded to 62% compared to 49% in the previous year, reflecting improvements in manufacturing processes and operational efficiencies.
Successful Share Buyback and Strong Cash Position
Bought back approximately $2.5 million shares, with additional cash inflow from warrant exercises, bringing nearly $3 million of additional cash. Maintained a strong cash position.
IVDR Accreditation Achievement
Successfully achieved IVDR accreditation for sales in the European Union, indicating progress in meeting higher regulatory standards.
Recombinant Antigen Program Initiation
Initiated a recombinant antigen program, expanding total addressable markets and enhancing product offerings.